Bio-Techne Corp

TECH is in Stage 2 advancing with bullish medium- and long-term trends, but price is extended above rising short-term EMAs and overbought conditions are evident. Execution posture: Stalk, waiting for a shallow pullback into the 9/21 EMA zone before committing long.

• ↑Q3 revenue $311.4M, organic growth +2% excl. timing issues
• ↑GMP proteins revenue grew ~50% YoY, underpinned by cytokine demand
• ↓Q3 revenue fell 2% YoY; emerging biotech down high single digits